{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T18:48:45Z","timestamp":1777056525655,"version":"3.51.4"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,10,27]],"date-time":"2018-10-27T00:00:00Z","timestamp":1540598400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s42000-018-0070-0","type":"journal-article","created":{"date-parts":[[2018,10,27]],"date-time":"2018-10-27T15:55:38Z","timestamp":1540655738000},"page":"117-126","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Medical therapy for non-functioning pituitary tumors\u2014a critical approach"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1152-9765","authenticated-orcid":false,"given":"Metaxia","family":"Tampourlou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Karapanou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitra A.","family":"Vassiliadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stylianos","family":"Tsagarakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,10,27]]},"reference":[{"key":"70_CR1","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s11102-012-0454-0","volume":"16","author":"M Gruppetta","year":"2013","unstructured":"Gruppetta M, Mercieca C, Vassallo J (2013) Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary 16:545\u2013553. https:\/\/doi.org\/10.1007\/s11102-012-0454-0","journal-title":"Pituitary"},{"key":"70_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1017\/cjn.2015.301","volume":"43","author":"K Al-Dahmani","year":"2016","unstructured":"Al-Dahmani K, Mohammad S, Imran F (2016) Sellar masses: an epidemiological study. Can J Neurol Sci 43:291\u2013297. https:\/\/doi.org\/10.1017\/cjn.2015.301","journal-title":"Can J Neurol Sci"},{"key":"70_CR3","doi-asserted-by":"publisher","first-page":"4769","DOI":"10.1210\/jc.2006-1668","volume":"91","author":"AF Daly","year":"2006","unstructured":"Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A (2006) High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab 91:4769\u20134775. https:\/\/doi.org\/10.1210\/jc.2006-1668","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol 72:377\u2013382. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03667.x","journal-title":"Clin Endocrinol"},{"key":"70_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1530\/EJE-13-0515","volume":"169","author":"M Losa","year":"2013","unstructured":"Losa M, Donofrio CA, Barzaghi R, Mortini P (2013) Presentation and surgical results of incidentally discovered nonfunctioning pituitary adenomas: evidence for a better outcome independently of other patients\u2019 characteristics. Eur J Endocrinol 169:735\u2013742. https:\/\/doi.org\/10.1530\/EJE-13-0515","journal-title":"Eur J Endocrinol"},{"key":"70_CR6","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1210\/jc.2010-1048","volume":"96","author":"PU Freda","year":"2011","unstructured":"Freda PU, Beckers AM, Katznelson L et al (2011) Pituitary incidentaloma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:894\u2013904. https:\/\/doi.org\/10.1210\/jc.2010-1048","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1159\/000339823","volume":"96","author":"Y Chen","year":"2012","unstructured":"Chen Y, Wang CD, Su ZP et al (2012) Natural history of postoperative nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Neuroendocrinology 96:333\u2013342. https:\/\/doi.org\/10.1159\/000339823","journal-title":"Neuroendocrinology"},{"key":"70_CR8","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1111\/j.1365-2265.2009.03542.x","volume":"70","author":"Y Greenman","year":"2009","unstructured":"Greenman Y, Stern N (2009) How should a nonfunctioning pituitary macroadenoma be monitored after debulking surgery? Clin Endocrinol 70:829\u2013832. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03542.x","journal-title":"Clin Endocrinol"},{"key":"70_CR9","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1210\/jc.2003-030859","volume":"89","author":"R Pivonello","year":"2004","unstructured":"Pivonello R, Matrone C, Filippella M et al (2004) Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab 89:1674\u20131683. https:\/\/doi.org\/10.1210\/jc.2003-030859","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1530\/EJE-16-0206","volume":"175","author":"Y Greenman","year":"2016","unstructured":"Greenman Y, Cooper O, Yaish I et al (2016) Treatment of clinically nonfunctioning pituitary adenomas with dopamine agonists. Eur J Endocrinol 175:63\u201372. https:\/\/doi.org\/10.1530\/EJE-16-0206","journal-title":"Eur J Endocrinol"},{"key":"70_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12022-017-9498-z","volume":"28","author":"O Mete","year":"2017","unstructured":"Mete O, Lopes MB (2017) Overview of the 2017 WHO classification of pituitary tumors. Endocr Pathol 28:228\u2013243. https:\/\/doi.org\/10.1007\/s12022-017-9498-z","journal-title":"Endocr Pathol"},{"key":"70_CR12","unstructured":"Asa SL (2008) Practical pituitary pathology: what does the pathologist need to know? Arch Pathol Lab Med 132:1231\u20131240. https:\/\/doi.org\/10.1043\/1543-2165(2008)132[1231:PPPWDT]2.0.CO;2"},{"key":"70_CR13","first-page":"610","volume":"33","author":"E Knosp","year":"1993","unstructured":"Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610\u2013617","journal-title":"Neurosurgery"},{"key":"70_CR14","doi-asserted-by":"publisher","first-page":"40792","DOI":"10.1038\/srep40792","volume":"7","author":"CC Chuang","year":"2017","unstructured":"Chuang CC, Lin SY, Pai PC, Yan JL, Toh CH, Lee ST et al (2017) Different volumetric measurement methods for pituitary adenomas and their crucial clinical significance. Sci Rep 7:40792. https:\/\/doi.org\/10.1038\/srep40792","journal-title":"Sci Rep"},{"key":"70_CR15","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1210\/edrv-13-2-220","volume":"13","author":"JS Bevan","year":"1992","unstructured":"Bevan JS, Webster J, Burke CW, Scanlon MF (1992) Dopamine agonists and pituitary tumor shrinkage. Endocr Rev 13:220\u2013240. https:\/\/doi.org\/10.1210\/edrv-13-2-220","journal-title":"Endocr Rev"},{"key":"70_CR16","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11102-005-1757-1","volume":"7","author":"PF Day","year":"2004","unstructured":"Day PF, Guitelman M, Artese R et al (2004) Retrospective multicentric study of pituitary incidentalomas. Pituitary 7:145\u2013148. https:\/\/doi.org\/10.1007\/s11102-005-1757-1","journal-title":"Pituitary"},{"key":"70_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1530\/eje.1.02334","volume":"156","author":"OM Dekkers","year":"2007","unstructured":"Dekkers OM, Hammer S, de Keizer RJ et al (2007) The natural course of nonfunctioning pituitary macroadenomas. Eur J Endocrinol 156:217\u2013224. https:\/\/doi.org\/10.1530\/eje.1.02334","journal-title":"Eur J Endocrinol"},{"key":"70_CR18","doi-asserted-by":"publisher","first-page":"g5390","DOI":"10.1136\/bmj.g5390","volume":"349","author":"A Rogers","year":"2014","unstructured":"Rogers A, Karavitaki N, Wass JA (2014) Diagnosis and management of prolactinomas and non-functioning pituitary adenomas. BMJ 349:g5390. https:\/\/doi.org\/10.1136\/bmj.g5390","journal-title":"BMJ"},{"key":"70_CR19","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1530\/eje.1.02298","volume":"155","author":"E Ferrante","year":"2006","unstructured":"Ferrante E, Ferraroni M, Castrignano T et al (2006) Non-functioning pituitary adenoma database: a useful resource to improve the clinical management of pituitary tumors. Eur J Endocrinol 155:823\u2013829. https:\/\/doi.org\/10.1530\/eje.1.02298","journal-title":"Eur J Endocrinol"},{"key":"70_CR20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3949\/ccjm.75.11.793","volume":"75","author":"D Serhal","year":"2008","unstructured":"Serhal D, Weil RJ, Hamrahian AH (2008) Evaluation and management of pituitary incidentalomas. Cleve Clin J Med 75:793\u2013801","journal-title":"Cleve Clin J Med"},{"key":"70_CR21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00006123-199702000-00001","volume":"40","author":"I Ciric","year":"1997","unstructured":"Ciric I, Ragin A, Baumgartner C, Pierce D (1997) Complications of transsphenoidal surgery: results of a national survey, review of the literature, and personal experience. Neurosurgery 40:225\u2013236","journal-title":"Neurosurgery"},{"key":"70_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1046\/j.1365-2265.2000.01153.x","volume":"53","author":"AC Woollons","year":"2000","unstructured":"Woollons AC, Hunn MK, Rajapakse YR et al (2000) Non-functioning pituitary adenomas: indications for postoperative radiotherapy. Clin Endocrinol 53:713\u2013717","journal-title":"Clin Endocrinol"},{"key":"70_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11102-011-0347-7","volume":"15","author":"F Roelfsema","year":"2012","unstructured":"Roelfsema F, Biermasz NR, Pereira AM (2012) Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15:71\u201383. https:\/\/doi.org\/10.1007\/s11102-011-0347-7","journal-title":"Pituitary"},{"key":"70_CR24","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s007010200064","volume":"144","author":"P Kremer","year":"2002","unstructured":"Kremer P, Forsting M, Ranaei G et al (2002) Magnetic resonance imaging after transsphenoidal surgery of clinically non-functional pituitary macroadenomas and its impact on detecting residual adenoma. Acta Neurochir 144:433\u2013443. https:\/\/doi.org\/10.1007\/s007010200064","journal-title":"Acta Neurochir"},{"key":"70_CR25","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1227\/01.NEU.0000255459.14764.BA","volume":"60","author":"P Mortini","year":"2007","unstructured":"Mortini P, Barzaghi R, Losa M, Boari N, Giovanelli M (2007) Surgical treatment of giant pituitary adenomas: strategies and results in a series of 95 consecutive patients. Neurosurgery 60:993\u20131002. https:\/\/doi.org\/10.1227\/01.NEU.0000255459.14764.BA","journal-title":"Neurosurgery"},{"key":"70_CR26","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1136\/jnnp.2004.035576","volume":"76","author":"KK Gnanalingham","year":"2005","unstructured":"Gnanalingham KK, Bhattacharjee S, Pennington R, Ng J, Mendoza N (2005) The time course of visual field recovery following transphenoidal surgery for pituitary adenomas: predictive factors for a good outcome. J Neurol Neurosurg Psychiatry 76:415\u2013419. https:\/\/doi.org\/10.1136\/jnnp.2004.035576","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"70_CR27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ecl.2007.10.011","volume":"37","author":"ME Molitch","year":"2008","unstructured":"Molitch ME (2008) Nonfunctioning pituitary tumors and pituitary incidentalomas. Endocrinol Metab Clin N Am 37:151\u2013171. https:\/\/doi.org\/10.1016\/j.ecl.2007.10.011","journal-title":"Endocrinol Metab Clin N Am"},{"key":"70_CR28","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/1097-0142(19910815)68:4<860::AID-CNCR2820680431>3.0.CO;2-4","volume":"68","author":"R Comtois","year":"1991","unstructured":"Comtois R, Beauregard H, Somma M, Serri O, Aris-Jilwan N, Hardy J (1991) The clinical and endocrine outcome to trans-sphenoidal microsurgery of nonsecreting pituitary adenomas. Cancer 68:860\u2013866","journal-title":"Cancer"},{"key":"70_CR29","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1227\/01.NEU.0000126885.71242.D7","volume":"55","author":"P Park","year":"2004","unstructured":"Park P, Chandler WF, Barkan AL et al (2004) The role of radiation therapy after surgical resection of nonfunctional pituitary macroadenomas. Neurosurgery 55:100\u2013106","journal-title":"Neurosurgery"},{"key":"70_CR30","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2016-4061","volume":"102","author":"M Tampourlou","year":"2017","unstructured":"Tampourlou M, Ntali G, Ahmed S et al (2017) Outcome of nonfunctioning pituitary adenomas that regrow after primary treatment: a study from two large UK centers. J Clin Endocrinol Metab 102:1889\u20131897. https:\/\/doi.org\/10.1210\/jc.2016-4061","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1530\/EJE-07-0099","volume":"157","author":"S Dubois","year":"2007","unstructured":"Dubois S, Guyetant S, Menei P et al (2007) Relevance of Ki-67 and prognostic factors for recurrence\/progression of gonadotropic adenomas after first surgery. Eur J Endocrinol 157:141\u2013147. https:\/\/doi.org\/10.1530\/EJE-07-0099","journal-title":"Eur J Endocrinol"},{"key":"70_CR32","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1530\/EJE-11-0566","volume":"165","author":"R Reddy","year":"2011","unstructured":"Reddy R, Cudlip S, Byrne JV, Karavitaki N, Wass JA (2011) Can we ever stop imaging in surgically treated and radiotherapy-naive patients with non-functioning pituitary adenoma? Eur J Endocrinol 165:739\u2013744. https:\/\/doi.org\/10.1530\/EJE-11-0566","journal-title":"Eur J Endocrinol"},{"key":"70_CR33","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1530\/EJE-10-0255","volume":"163","author":"S Brochier","year":"2010","unstructured":"Brochier S, Galland F, Kujas M et al (2010) Factors predicting relapse of nonfunctioning pituitary macroadenomas after neurosurgery: a study of 142 patients. Eur J Endocrinol 163:193\u2013200. https:\/\/doi.org\/10.1530\/EJE-10-0255","journal-title":"Eur J Endocrinol"},{"key":"70_CR34","doi-asserted-by":"publisher","first-page":"736","DOI":"10.3171\/JNS\/2008\/108\/4\/0736","volume":"108","author":"EF Chang","year":"2008","unstructured":"Chang EF, Zada G, Kim S et al (2008) Long-term recurrence and mortality after surgery and adjuvant radiotherapy for nonfunctional pituitary adenomas. J Neurosurg 108:736\u2013745. https:\/\/doi.org\/10.3171\/JNS\/2008\/108\/4\/0736","journal-title":"J Neurosurg"},{"key":"70_CR35","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/micr.1920151103","volume":"15","author":"SY Yang","year":"1994","unstructured":"Yang SY, Zhu T, Zhang JN, Sun YS (1994) Transsphenoidal microsurgical management of pituitary adenomas. Microsurgery 15:754\u2013759","journal-title":"Microsurgery"},{"issue":"7","key":"70_CR36","first-page":"398","volume":"2","author":"ML Jaffrain-Rea","year":"1993","unstructured":"Jaffrain-Rea ML, Derome P, Bataini JP et al (1993) Influence of radiotherapy on long-term relapse in clinically non-secreting pituitary adenomas. A retrospective study (1970-1988). Eur J Med 2(7):398\u2013403","journal-title":"Eur J Med"},{"key":"70_CR37","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3171\/JNS\/2008\/108\/3\/0525","volume":"108","author":"M Losa","year":"2008","unstructured":"Losa M, Mortini P, Barzaghi R et al (2008) Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 108:525\u2013532. https:\/\/doi.org\/10.3171\/JNS\/2008\/108\/3\/0525","journal-title":"J Neurosurg"},{"key":"70_CR38","doi-asserted-by":"publisher","first-page":"3368","DOI":"10.1210\/jc.2017-00773","volume":"102","author":"G Raverot","year":"2017","unstructured":"Raverot G, Dantony E, Beauvy J et al (2017) Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification. J Clin Endocrinol Metab 102:3368\u20133374. https:\/\/doi.org\/10.1210\/jc.2017-00773","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR39","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1210\/jc.2005-2552","volume":"91","author":"OM Dekkers","year":"2006","unstructured":"Dekkers OM, Pereira AM, Roelfsema F et al (2006) Observation alone after transsphenoidal surgery for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 91:1796\u20131801. https:\/\/doi.org\/10.1210\/jc.2005-2552","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR40","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/j.1365-2265.2009.03583.x","volume":"71","author":"EP O\u2019Sullivan","year":"2009","unstructured":"O\u2019Sullivan EP, Woods C, Glynn N et al (2009) The natural history of surgically treated but radiotherapy-naive nonfunctioning pituitary adenomas. Clin Endocrinol 71:709\u2013714. https:\/\/doi.org\/10.1111\/j.1365-2265.2009.03583.x","journal-title":"Clin Endocrinol"},{"key":"70_CR41","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1046\/j.1365-2265.2003.01784.x","volume":"58","author":"Y Greenman","year":"2003","unstructured":"Greenman Y, Ouaknine G, Veshchev I, Reider-Groswasser II, Segev Y, Stern N (2003) Postoperative surveillance of clinically nonfunctioning pituitary macroadenomas: markers of tumour quiescence and regrowth. Clin Endocrinol 58:763\u2013769","journal-title":"Clin Endocrinol"},{"key":"70_CR42","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/cen.13402","volume":"87","author":"J Ratnasingam","year":"2017","unstructured":"Ratnasingam J, Lenders N, Ong B et al (2017) Predictors for secondary therapy after surgical resection of nonfunctioning pituitary adenomas. Clin Endocrinol 87:717\u2013724. https:\/\/doi.org\/10.1111\/cen.13402","journal-title":"Clin Endocrinol"},{"key":"70_CR43","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1210\/jc.2011-0251","volume":"96","author":"JS Loeffler","year":"2011","unstructured":"Loeffler JS, Shih HA (2011) Radiation therapy in the management of pituitary adenomas. J Clin Endocrinol Metab 96:1992\u20132003. https:\/\/doi.org\/10.1210\/jc.2011-0251","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR44","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3171\/2013.3.JNS12766","volume":"119","author":"JP Sheehan","year":"2013","unstructured":"Sheehan JP, Starke RM, Mathieu D et al (2013) Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. J Neurosurg 119:446\u2013456. https:\/\/doi.org\/10.3171\/2013.3.JNS12766","journal-title":"J Neurosurg"},{"key":"70_CR45","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1046\/j.1365-2265.1998.00393.x","volume":"48","author":"NJ Gittoes","year":"1998","unstructured":"Gittoes NJ, Bates AS, Tse W et al (1998) Radiotherapy for non-function pituitary tumours. Clin Endocrinol 48:331\u2013337","journal-title":"Clin Endocrinol"},{"key":"70_CR46","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.jocn.2011.07.025","volume":"19","author":"PJ Wilson","year":"2012","unstructured":"Wilson PJ, De-Loyde KJ, Williams JR, Smee RI (2012) A single centre\u2019s experience of stereotactic radiosurgery and radiotherapy for non-functioning pituitary adenomas with the Linear Accelerator (Linac). J Clin Neurosci 19:370\u2013374. https:\/\/doi.org\/10.1016\/j.jocn.2011.07.025","journal-title":"J Clin Neurosci"},{"key":"70_CR47","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1093\/neuonc\/nor055","volume":"13","author":"H Iwata","year":"2011","unstructured":"Iwata H, Sato K, Tatewaki K et al (2011) Hypofractionated stereotactic radiotherapy with CyberKnife for nonfunctioning pituitary adenoma: high local control with low toxicity. Neuro-Oncology 13:916\u2013922. https:\/\/doi.org\/10.1093\/neuonc\/nor055","journal-title":"Neuro-Oncology"},{"key":"70_CR48","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1530\/EJE-14-0872","volume":"172","author":"G Minniti","year":"2015","unstructured":"Minniti G, Scaringi C, Poggi M et al (2015) Fractionated stereotactic radiotherapy for large and invasive non-functioning pituitary adenomas: long-term clinical outcomes and volumetric MRI assessment of tumor response. Eur J Endocrinol 172:433\u2013441. https:\/\/doi.org\/10.1530\/EJE-14-0872","journal-title":"Eur J Endocrinol"},{"key":"70_CR49","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1210\/jc.2016-3402","volume":"102","author":"P Burman","year":"2017","unstructured":"Burman P, van Beek AP, Biller BM, Camacho-H\u00fcbner C, Mattsson AF (2017) Radiotherapy, especially at young age, increases the risk for de novo brain tumors in patients treated for pituitary\/sellar lesions. J Clin Endocrinol Metab 102:1051\u20131058. https:\/\/doi.org\/10.1210\/jc.2016-3402","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR50","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1210\/jc.2014-3697","volume":"100","author":"NC Varsseveld van","year":"2015","unstructured":"van Varsseveld NC, van Bunderen CC, Ubachs DH et al (2015) Cerebrovascular events, secondary intracranial tumors, and mortality after radiotherapy for nonfunctioning pituitary adenomas: a subanalysis from the Dutch National Registry of Growth Hormone Treatment in Adults. J Clin Endocrinol Metab 100:1104\u20131112. https:\/\/doi.org\/10.1210\/jc.2014-3697","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR51","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1210\/jc.2008-1826","volume":"94","author":"LV Neto","year":"2009","unstructured":"Neto LV, Machado Ede O, Luque RM et al (2009) Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab 94:1931\u20131937. https:\/\/doi.org\/10.1210\/jc.2008-1826","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR52","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s11102-011-0316-1","volume":"15","author":"F Gabalec","year":"2012","unstructured":"Gabalec F, Beranek M, Netuka D et al (2012) Dopamine 2 receptor expression in various pathological types of clinically non-functioning pituitary adenomas. Pituitary 15:222\u2013226. https:\/\/doi.org\/10.1007\/s11102-011-0316-1","journal-title":"Pituitary"},{"key":"70_CR53","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1677\/ERC-07-0271","volume":"15","author":"T Florio","year":"2008","unstructured":"Florio T, Barbieri F, Spaziante R et al (2008) Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr Relat Cancer 15:583\u2013596. https:\/\/doi.org\/10.1677\/ERC-07-0271","journal-title":"Endocr Relat Cancer"},{"key":"70_CR54","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1677\/ERC-08-0181","volume":"15","author":"A Colao","year":"2008","unstructured":"Colao A, Di Somma C, Pivonello R, Faggiano A, Lombardi G, Savastano S (2008) Medical therapy for clinically nonfunctioning pituitary adenomas. Endocr Relat Cancer 15:905\u2013915. https:\/\/doi.org\/10.1677\/ERC-08-0181","journal-title":"Endocr Relat Cancer"},{"key":"70_CR55","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/cen.12684","volume":"82","author":"L Vieira Neto","year":"2015","unstructured":"Vieira Neto L, Wildemberg LE, Moraes AB et al (2015) Dopamine receptor subtype 2 expression profile in nonfunctioning pituitary adenomas and in vivo response to cabergoline therapy. Clin Endocrinol 82:739\u2013746. https:\/\/doi.org\/10.1111\/cen.12684","journal-title":"Clin Endocrinol"},{"key":"70_CR56","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11102-012-0403-y","volume":"16","author":"EC Garcia","year":"2013","unstructured":"Garcia EC, Naves LA, Silva AO, de Castro LF, Casulari LA, Azevedo MF (2013) Short-term treatment with cabergoline can lead to tumor shrinkage in patients with nonfunctioning pituitary adenomas. Pituitary 16:189\u2013194. https:\/\/doi.org\/10.1007\/s11102-012-0403-y","journal-title":"Pituitary"},{"key":"70_CR57","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"MP Gillam","year":"2006","unstructured":"Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27:485\u2013534. https:\/\/doi.org\/10.1210\/er.2005-9998","journal-title":"Endocr Rev"},{"key":"70_CR58","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1001\/jamainternmed.2014.5262","volume":"174","author":"TJ Moore","year":"2014","unstructured":"Moore TJ, Glenmullen J, Mattison DR (2014) Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 174:1930\u20131933. https:\/\/doi.org\/10.1001\/jamainternmed.2014.5262","journal-title":"JAMA Intern Med"},{"key":"70_CR59","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1210\/jc.2009-2095","volume":"95","author":"E Valassi","year":"2010","unstructured":"Valassi E, Klibanski A, Biller BM (2010) Clinical review#: potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 95:1025\u20131033. https:\/\/doi.org\/10.1210\/jc.2009-2095","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR60","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1210\/jc.2013-2254","volume":"99","author":"WM Drake","year":"2014","unstructured":"Drake WM, Stiles CE, Howlett TA, Toogood AA, Bevan JS, Steeds RP (2014) A cross sectional study of the prevalence of cardiac valvular abnormalities in hyperprolactinemic patients treated with ergot-derived dopamine agonists. J Clin Endocrinol Metab 99:90\u201396. https:\/\/doi.org\/10.1210\/jc.2013-2254","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR61","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1530\/eje.1.02349","volume":"156","author":"WW Herder de","year":"2007","unstructured":"de Herder WW, Reijs AE, Feelders RA et al (2007) Diagnostic imaging of dopamine receptors in pituitary adenomas. Eur J Endocrinol 156:S53\u2013S56. https:\/\/doi.org\/10.1530\/eje.1.02349","journal-title":"Eur J Endocrinol"},{"key":"70_CR62","doi-asserted-by":"crossref","first-page":"369","DOI":"10.33549\/physiolres.932821","volume":"64","author":"F Gabalec","year":"2015","unstructured":"Gabalec F, Drastikova M, Cesak T et al (2015) Dopamine 2 and somatostatin 1-5 receptors coexpression in clinically non-functioning pituitary adenomas. Physiol Res 64:369\u2013377","journal-title":"Physiol Res"},{"key":"70_CR63","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s11154-008-9086-0","volume":"10","author":"A Saveanu","year":"2009","unstructured":"Saveanu A, Jaquet P (2009) Somatostatin-dopamine ligands in the treatment of pituitary adenomas. Rev Endocr Metab Disord 10:83\u201390. https:\/\/doi.org\/10.1007\/s11154-008-9086-0","journal-title":"Rev Endocr Metab Disord"},{"key":"70_CR64","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1530\/eje.1.02313","volume":"156","author":"GF Taboada","year":"2007","unstructured":"Taboada GF, Luque RM, Bastos W et al (2007) Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156:65\u201374. https:\/\/doi.org\/10.1530\/eje.1.02313","journal-title":"Eur J Endocrinol"},{"key":"70_CR65","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1210\/jc.2011-3163","volume":"97","author":"C Ramirez","year":"2012","unstructured":"Ramirez C, Cheng S, Vargas G et al (2012) Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. J Clin Endocrinol Metab 97:1745\u20131751. https:\/\/doi.org\/10.1210\/jc.2011-3163","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR66","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.mce.2007.11.024","volume":"286","author":"A Ben-Shlomo","year":"2008","unstructured":"Ben-Shlomo A, Melmed S (2008) Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol 286:192\u2013198. https:\/\/doi.org\/10.1016\/j.mce.2007.11.024","journal-title":"Mol Cell Endocrinol"},{"key":"70_CR67","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1530\/eje.0.1410396","volume":"141","author":"T Florio","year":"1999","unstructured":"Florio T, Thellung S, Arena S et al (1999) Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur J Endocrinol 141:396\u2013408","journal-title":"Eur J Endocrinol"},{"key":"70_CR68","first-page":"179","volume":"58","author":"M Pawlikowski","year":"2007","unstructured":"Pawlikowski M, Lawnicka H, Pisarek H, Kunert-Radek J, Radek M, Culler MD (2007) Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alphasubunit (alpha-SU) release from \u201cclinically nonfunctioning\u201d pituitary adenoma cells incubated in vitro. J Physiol Pharmacol 58:179\u2013188","journal-title":"J Physiol Pharmacol"},{"key":"70_CR69","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.mce.2007.12.011","volume":"286","author":"H Padova","year":"2008","unstructured":"Padova H, Rubinfeld H, Hadani M et al (2008) Effects of selective somatostatin analogs and cortistatin on cell viability in cultured human non-functioning pituitary adenomas. Mol Cell Endocrinol 286:214\u2013218. https:\/\/doi.org\/10.1016\/j.mce.2007.12.011","journal-title":"Mol Cell Endocrinol"},{"key":"70_CR70","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s11102-011-0370-8","volume":"15","author":"A Fusco","year":"2012","unstructured":"Fusco A, Giampietro A, Bianchi A et al (2012) Treatment with octreotide LAR in clinically non-functioning pituitary adenoma: results from a case-control study. Pituitary 15:571\u2013578. https:\/\/doi.org\/10.1007\/s11102-011-0370-8","journal-title":"Pituitary"},{"key":"70_CR71","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1159\/000080741","volume":"80","author":"HA Schmid","year":"2004","unstructured":"Schmid HA, Schoeffter P (2004) Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80:47\u201350. https:\/\/doi.org\/10.1159\/000080741","journal-title":"Neuroendocrinology"},{"key":"70_CR72","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1007\/s11102-016-0734-1","volume":"19","author":"JM Silverstein","year":"2016","unstructured":"Silverstein JM (2016) Hyperglycemia induced by pasireotide in patients with Cushing\u2019s disease or acromegaly. Pituitary 19:536\u2013543. https:\/\/doi.org\/10.1007\/s11102-016-0734-1","journal-title":"Pituitary"},{"key":"70_CR73","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/j.cellsig.2007.07.007","volume":"19","author":"A Baragli","year":"2007","unstructured":"Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U (2007) Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2 Co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal 19:2304\u20132316. https:\/\/doi.org\/10.1016\/j.cellsig.2007.07.007","journal-title":"Cell Signal"},{"key":"70_CR74","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000371806","volume":"101","author":"E Chatzellis","year":"2015","unstructured":"Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G (2015) Aggressive pituitary tumors. Neuroendocrinology 101:87\u2013104. https:\/\/doi.org\/10.1159\/000371806","journal-title":"Neuroendocrinology"},{"key":"70_CR75","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot G, Burman P, McCormack A et al (2018) European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol 178:G1\u2013G24. https:\/\/doi.org\/10.1530\/EJE-17-0796","journal-title":"Eur J Endocrinol"},{"key":"70_CR76","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s11102-016-0745-y","volume":"20","author":"C Halevy","year":"2017","unstructured":"Halevy C, Whitelaw BC (2017) How effective is temozolomide for treating pituitary tumours and when should it be used? Pituitary 20:261\u2013266. https:\/\/doi.org\/10.1007\/s11102-016-0745-y","journal-title":"Pituitary"},{"key":"70_CR77","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1530\/EJE-16-0979","volume":"176","author":"H Lasolle","year":"2017","unstructured":"Lasolle H, Cortet C, Castinetti F et al (2017) Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas. Eur J Endocrinol 176:769\u2013777. https:\/\/doi.org\/10.1530\/EJE-16-0979","journal-title":"Eur J Endocrinol"},{"key":"70_CR78","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1210\/jc.2014-4350","volume":"100","author":"D Bengtsson","year":"2015","unstructured":"Bengtsson D, Schroder HD, Andersen M et al (2015) Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. J Clin Endocrinol Metab 100:1689\u20131698. https:\/\/doi.org\/10.1210\/jc.2014-4350","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR79","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1111\/j.1365-2362.2011.02520.x","volume":"41","author":"AI McCormack","year":"2011","unstructured":"McCormack AI, Wass JA, Grossman AB (2011) Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Investig 41:1133\u20131148. https:\/\/doi.org\/10.1111\/j.1365-2362.2011.02520.x","journal-title":"Eur J Clin Investig"},{"key":"70_CR80","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996. https:\/\/doi.org\/10.1056\/NEJMoa043330","journal-title":"N Engl J Med"},{"key":"70_CR81","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11060-015-1991-y","volume":"126","author":"M Losa","year":"2016","unstructured":"Losa M, Bogazzi F, Cannavo S et al (2016) Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas. J Neuro-Oncol 126:519\u2013525. https:\/\/doi.org\/10.1007\/s11060-015-1991-y","journal-title":"J Neuro-Oncol"},{"key":"70_CR82","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1210\/jc.2012-2924","volume":"98","author":"T Hirohata","year":"2013","unstructured":"Hirohata T, Asano K, Ogawa Y et al (2013) DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. J Clin Endocrinol Metab 98:1130\u20131136. https:\/\/doi.org\/10.1210\/jc.2012-2924","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR83","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1210\/jc.2010-0644","volume":"95","author":"G Raverot","year":"2010","unstructured":"Raverot G, Sturm N, de Fraipont F et al (2010) Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 95:4592\u20134599. https:\/\/doi.org\/10.1210\/jc.2010-0644","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR84","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/j.1365-2265.2012.04381.x","volume":"76","author":"G Raverot","year":"2012","unstructured":"Raverot G, Castinetti F, Jouanneau E et al (2012) Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol 76:769\u2013775. https:\/\/doi.org\/10.1111\/j.1365-2265.2012.04381.x","journal-title":"Clin Endocrinol"},{"key":"70_CR85","doi-asserted-by":"publisher","first-page":"160021","DOI":"10.1530\/EDM-16-0021","volume":"2016","author":"F Keane","year":"2016","unstructured":"Keane F, Egan AM, Navin P, Brett F, Dennedy MC (2016) Gonadotropin-releasing hormone agonist-induced pituitary apoplexy. Endocrinol Diabetes Metab Case Rep 2016:160021. https:\/\/doi.org\/10.1530\/EDM-16-0021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"70_CR86","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s11102-013-0494-0","volume":"17","author":"J Komor","year":"2014","unstructured":"Komor J, Reubi JC, Christ ER (2014) Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma. Pituitary 17:227\u2013231. https:\/\/doi.org\/10.1007\/s11102-013-0494-0","journal-title":"Pituitary"},{"key":"70_CR87","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1007\/s11102-013-0540-y","volume":"17","author":"J Maclean","year":"2014","unstructured":"Maclean J, Aldridge M, Bomanji J, Short S, Fersht N (2014) Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma\/carcinoma: variable clinical response in preliminary evaluation. Pituitary 17:530\u2013538. https:\/\/doi.org\/10.1007\/s11102-013-0540-y","journal-title":"Pituitary"},{"key":"70_CR88","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1210\/en.2012-2128","volume":"154","author":"X Liu","year":"2013","unstructured":"Liu X, Ma S, Dai C et al (2013) Antiproliferative, antiinvasive, and proapoptotic activity of folate receptor alpha-targeted liposomal doxorubicin in nonfunctional pituitary adenoma cells. Endocrinology 154:1414\u20131423. https:\/\/doi.org\/10.1210\/en.2012-2128","journal-title":"Endocrinology"},{"key":"70_CR89","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1210\/jc.2009-1641","volume":"95","author":"MC Zatelli","year":"2010","unstructured":"Zatelli MC, Minoia M, Filieri C et al (2010) Effect of everolimus on cell viability in nonfunctioning pituitary adenomas. J Clin Endocrinol Metab 95:968\u2013976. https:\/\/doi.org\/10.1210\/jc.2009-1641","journal-title":"J Clin Endocrinol Metab"},{"key":"70_CR90","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1158\/1078-0432.CCR-15-0288","volume":"21","author":"M Lee","year":"2015","unstructured":"Lee M, Wiedemann T, Gross C et al (2015) Targeting PI3K\/mTOR signaling displays potent antitumor efficacy against nonfunctioning pituitary adenomas. Clin Cancer Res 21:3204\u20133215. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0288","journal-title":"Clin Cancer Res"},{"key":"70_CR91","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1210\/er.2009-0033","volume":"31","author":"M Sherlock","year":"2010","unstructured":"Sherlock M, Ayuk J, Tomlinson JW et al (2010) Mortality in patients with pituitary disease. Endocr Rev 31:301\u2013342. https:\/\/doi.org\/10.1210\/er.2009-0033","journal-title":"Endocr Rev"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-018-0070-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s42000-018-0070-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-018-0070-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,14]],"date-time":"2020-11-14T05:15:51Z","timestamp":1605330951000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s42000-018-0070-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,27]]},"references-count":91,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["70"],"URL":"https:\/\/doi.org\/10.1007\/s42000-018-0070-0","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,27]]},"assertion":[{"value":"1 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}